332 related articles for article (PubMed ID: 33657372)
21. The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression.
Sadasivam S; Duan S; DeCaprio JA
Genes Dev; 2012 Mar; 26(5):474-89. PubMed ID: 22391450
[TBL] [Abstract][Full Text] [Related]
22. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.
Kim IM; Ackerson T; Ramakrishna S; Tretiakova M; Wang IC; Kalin TV; Major ML; Gusarova GA; Yoder HM; Costa RH; Kalinichenko VV
Cancer Res; 2006 Feb; 66(4):2153-61. PubMed ID: 16489016
[TBL] [Abstract][Full Text] [Related]
23. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
[TBL] [Abstract][Full Text] [Related]
24. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
25. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
[TBL] [Abstract][Full Text] [Related]
26. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
27. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.
Chaudhary R; Slebos RJC; Song F; McCleary-Sharpe KP; Masannat J; Tan AC; Wang X; Amaladas N; Wu W; Hall GE; Conejo-Garcia JR; Hernandez-Prera JC; Chung CH
Mol Carcinog; 2021 Feb; 60(2):138-150. PubMed ID: 33378592
[TBL] [Abstract][Full Text] [Related]
28. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
29. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.
Zhang X; Lv QL; Huang YT; Zhang LH; Zhou HH
J Exp Clin Cancer Res; 2017 Aug; 36(1):105. PubMed ID: 28784180
[TBL] [Abstract][Full Text] [Related]
30. FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway.
Wang K; Zhu X; Zhang K; Zhu L; Zhou F
Acta Biochim Biophys Sin (Shanghai); 2016 Sep; 48(9):804-9. PubMed ID: 27521795
[TBL] [Abstract][Full Text] [Related]
31. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
32. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Li M; Yang J; Zhou W; Ren Y; Wang X; Chen H; Zhang J; Chen J; Sun Y; Cui L; Liu X; Wang L; Wu C
Br J Cancer; 2017 Sep; 117(7):974-983. PubMed ID: 28850563
[TBL] [Abstract][Full Text] [Related]
33. Induction of endomitosis-like event in HeLa cells following CHK1 inhibitor treatment.
Homma H; Nojima H; Kaida A; Miura M
Biochem Biophys Res Commun; 2019 Dec; 520(2):492-497. PubMed ID: 31610912
[TBL] [Abstract][Full Text] [Related]
34. Co-regulation and function of
Barger CJ; Chee L; Albahrani M; Munoz-Trujillo C; Boghean L; Branick C; Odunsi K; Drapkin R; Zou L; Karpf AR
Elife; 2021 Apr; 10():. PubMed ID: 33890574
[TBL] [Abstract][Full Text] [Related]
35. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity.
Prasad CB; Oo A; Liu Y; Qiu Z; Zhong Y; Li N; Singh D; Xin X; Cho YJ; Li Z; Zhang X; Yan C; Zheng Q; Wang QE; Guo D; Kim B; Zhang J
Nat Commun; 2024 May; 15(1):4667. PubMed ID: 38821952
[TBL] [Abstract][Full Text] [Related]
36. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
Nilsson MB; Sun H; Robichaux J; Pfeifer M; McDermott U; Travers J; Diao L; Xi Y; Tong P; Shen L; Hofstad M; Kawakami M; Le X; Liu X; Fan Y; Poteete A; Hu L; Negrao MV; Tran H; Dmitrovsky E; Peng D; Gibbons DL; Wang J; Heymach JV
Sci Transl Med; 2020 Sep; 12(559):. PubMed ID: 32878980
[TBL] [Abstract][Full Text] [Related]
37. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.
Iness AN; Felthousen J; Ananthapadmanabhan V; Sesay F; Saini S; Guiley KZ; Rubin SM; Dozmorov M; Litovchick L
Oncogene; 2019 Feb; 38(7):1080-1092. PubMed ID: 30206359
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
39. Sterigmatocystin-induced checkpoint adaptation depends on Chk1 in immortalized human gastric epithelial cells in vitro.
Jiang X; Wang J; Xing L; Shen H; Lian W; Yi L; Zhang D; Yang H; Liu J; Zhang X
Arch Toxicol; 2017 Jan; 91(1):259-270. PubMed ID: 26914363
[TBL] [Abstract][Full Text] [Related]
40. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers.
Moens S; Zhao P; Baietti MF; Marinelli O; Van Haver D; Impens F; Floris G; Marangoni E; Neven P; Annibali D; Sablina AA; Amant F
Sci Rep; 2021 Feb; 11(1):3176. PubMed ID: 33542435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
